Oxybutynin Hydrochloride

ApprovedSmall molecule

Oxybutynin Hydrochloride is one of 36 small molecule programs targeting Neurogenic bladder. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neurogenic BladderActive, not recruiting

Multiple SclerosisActive, not recruiting

Neurogenic BladderPhase 3

Active, not recruiting

Multiple SclerosisApproved

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Oxybutynin Hydrochloride

Astellas

Approved

1 2

Betaseron

Bayer

Preclinical

16 3

Avonex

EMD Serono

Preclinical

22 4

Zinbryta

Roche

Preclinical

2 5

Flomax

Sanofi

Preclinical

1 6

Pred Forte

Myfortic

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

3 9

Pletal

Otsuka

Preclinical

1 10

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Not yet recruiting

Neurogenic Bladder

NCT07027020

Clinical

Trials by Indication[1]

Neurogenic bladder1 trial

Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction

Not yet recruiting·—·Phase 3·NCT07027020·60 enrolled

Multiple Sclerosis1 trial

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis

Completed· Astellas logo

Astellas·Phase 4·NCT00629642·249 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Oxybutynin Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxybutynin Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxybutynin Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Astellas

Oxybutynin Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Neurogenic bladder1 trial

Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News